

Meet us at Booth #213

Sunday 5 November

Short course • ROOM TBD • 13:00 - 17:00

| Code | Topic | Presenter |
|--|---|-----------|
| USE OF PHARMACOECONOMIC / ECONOMIC / OUTCOMES RESEARCH INFORMATION | | |
| | REIMBURSEMENT SYSTEMS FOR PHARMACEUTICALS IN EUROPE | TOUMI M |

Monday 6 November

Research Posters • SESSION 1 • 08:45 - 13:45

| Code | Topic | Presenter |
|--|---|--|
| URINARY /KIDNEY DISORDERS - HEALTH CARE USE & POLICY STUDIES | | |
| PUK26 N32 | BURDEN OF ILLNESS ASSOCIATED WITH ANAEMIA IN CHRONIC KIDNEY DISEASE IN JAPAN: A LITERATURE REVIEW | AKIZAWA T, OKUMURA H, ALEXANDRE AF, FUKUSHIMA A, KIYABU G, DOREY J |

Research Posters • SESSION 2 • 15:45 - 19:30

| Code | Topic | Presenter |
|--|---|--|
| INDIVIDUAL'S HEALTH - PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE STUDIES | | |
| PIH21 G8 | PATIENTS' PREFERENCES RELATED TO TREATMENTS FOR ENDOMETRIOSIS-RELATED PAIN: RESULTS OF A DISCRETE CHOICE EXPERIMENT IN THE UK | GERMAIN N, ABALLÉA S, ANDERSSON FL, KORCHAGINA D, HAWKEN NA, TOUMI M |
| SYSTEMIC DISORDERS/CONDITIONS - Health Care Use & Policy Studies | | |
| PSY115 M24 | HOW SHOULD WE VALUE ORPHAN DRUGS? SUGGESTIONS FROM A LARGE PUBLIC OPINION SURVEY | KORCHAGINA D, TOUMI M, ABALLEA S, MILLIER A, FAUSSARD B |

Issue Panels • 14:15 - 15:15

| Code | Topic | Presenter |
|--|---|--|
| HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUES | | |
| IP4 | VALUE ADDED MEDICINES: TIME TO ADJUST THE HEALTH TECHNOLOGY ASSESSMENT DECISION FRAMEWORKS? | MODERATOR: MICHAEL DRUMMOND, PANELISTS: PASCAL AUGQUIER, LUIGI BURGIO, MONDHER TOUMI |

Podium Presentation • 16:15 - 16:45

| Code | Topic | Presenter |
|-----------------------|---|---|
| MENTAL HEALTH STUDIES | | |
| MH3 | MODEL STRUCTURE OF PATIENT-LEVEL MODELS FOR SCHIZOPHRENIA: A SYSTEMATIC LITERATURE REVIEW | ZHOU J, MILLIER A, DOREY J, ABALLEA S, TOUMI M |
| MH4 | FAMILY CAREGIVING IN DEMENTIA AND ITS IMPACT ON QUALITY OF LIFE AND ECONOMIC BURDEN IN JAPAN – WEB-BASED SURVEY | IGARASHI A, FUKUDA A, TENG L, MA F, DOREY J, ONISHI Y |

Meet with our researchers and scientific experts attending ISPOR.



Samuel Aballéa
PhD, MSc
Vice President, HEOR



Clément Francois
PhD, MSc
Vice President



Nicola Germain
MA
Manager, HEOR



Krzysztof Kloc
MSc
Associate Manager,
Pricing & Market Access

Research Posters • SESSION 3 • 08:45 - 13:30

| Code | Topic | Presenter |
|--|--|---|
| MEDICAL DEVICES/DIAGNOSTICS - COST STUDIES | | |
| PMD57 C2 | A COST CONSEQUENCES ANALYSIS OF THE HUMAN BODY POSTURIZER IN ITALY | BELFIORE P, D'AUSILIO A, AIELLO A, TOUMI M, SCALETTI A, FRAU A, RIPANI M, ROMANO SPICA V, LIGUORI G |
| RESPIRATORY-RELATED DISORDERS - PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE STUDIES | | |
| PRS51 N10 | EXPLORING THE BURDEN OF ILLNESS AND IMPACT OF SQ-STANDARDISED GRASS ALLERGY IMMUNOTHERAPY TABLET TREATMENT (AIT) ON QUALITY OF LIFE (QOL) IN PATIENTS WITH ALLERGIC RHINITIS (AR) IN GERMANY AND THE NETHERLANDS | GERMAIN N, ABALLEA S, ROMANO M, HAWKEN NA, TOUMI M |

Research Posters • SESSION 4 • 15:30 - 19:15

| Code | Topic | Presenter |
|--|---|--|
| HEALTH CARE USE & POLICY STUDIES - DRUG/DEVICE/DIAGNOSTIC USE & POLICY | | |
| PHP18 A18 | TRENDS IN EMERGING NON-HTA DRUG VALUE ASSESSMENT FRAMEWORKS | LACH K, KLOC K, CHOUAID C, BORGET I, RÉMUZAT C, TOUMI M |
| PHP32 B5 | E-HEALTH FUNDING IN EUROPE | YOUNG KE, SOUSSI I, KORNFELD M, TOUMI M |
| PHP44 B17 | POTENTIAL FUNDING SOURCES FOR BREAKTHROUGH THERAPIES | HANNA E, REMUZAT C, AUQUIER P, DUSSART C, TOUMI M |
| PHP52 B25 | USE OF PRAGMATIC CLINICAL TRIALS TO SUPPORT DRUG LAUNCH | RÉMUZAT C, KLOC K, TOUMI M |
| PHP61 C7 | EUROPEAN INITIATIVES TO ENHANCE BIOSIMILAR ADOPTION | KAPUZNIAK A, RÉMUZAT C, TOUMI M |
| HEALTH CARE USE & POLICY STUDIES - FORMULARY DEVELOPMENT | | |
| PHP82 D1 | AN INTRODUCTIVE ANALYSIS OF THE TIMEFRAME FROM EUROPEAN DRUGS APPROVAL TO THE SICILIAN HOSPITAL FORMULARY INCLUSION | AIELLO A, D'AUSILIO A, PIZZIMENTI V, FORMICA D, SULTANA J, LUCCHESI S, IENTILE V, TOUMI M, TRIFIRÒ G |
| HEALTH CARE USE & POLICY STUDIES - HEALTH CARE COSTS & MANAGEMENT | | |
| PHP97 D16 | BUDGET IMPACT OF NEWLY APPROVED DRUGS BY THE SICILIAN DRUG FORMULARY COMMITTEE: AN INTRODUCTIVE ANALYSIS | AIELLO A, D'AUSILIO A, PIZZIMENTI V, FORMICA D, SULTANA J, LUCCHESI S, IENTILE V, TOUMI M, TRIFIRÒ G |
| PHP115 E6 | COULD HEALTHCOIN BE A REVOLUTION IN HEALTHCARE? | HANNA E, REMUZAT C, AUQUIER P, DUSSART C, TOUMI M |
| HEALTH CARE USE & POLICY STUDIES - HEALTH CARE COSTS & MANAGEMENT | | |
| PHP309 K3 | VALUE ADDED MEDICINES: ADJUSTEMENTS OF HTA DECISION FRAMEWORKS TO CAPTURE THEIR FULL VALUE | RÉMUZAT C, TOUMI M |
| PHP313 K7 | SPECIFICITIES OF CANCER IMMUNOTHERAPY – CHALLENGES FROM MARKET ACCESS PERSPECTIVE | LACH K, CHOUAID C, RÉMUZAT C, TOUMI M |
| MENTAL HEALTH - CLINICAL OUTCOMES STUDIES | | |
| PMH2 K22 | A NETWORK META-ANALYSIS TO COMPARE THE EFFICACY AND SAFETY OF ANTIPSYCHOTICS AS MAINTENANCE TREATMENT FOR PATIENTS WITH SCHIZOPHRENIA | MILLIER A, ZINEDDINE O, ZHOU J, ABALLEA S, TAIEB V, TOUMI M |



Agathe Leray
MSc
Director,
Business Development



Caroline Marre
MSc
Senior Manager,
Pricing & Market Access



Aurélie Millier
PhD, MSc
Principal Consultant,
HEOR



Monika Mos
MSc
Business Development
Specialist



Leyla Mohseninejad
M.Eng, PhD
Lead Consultant,
HEOR

Wednesday 8 November

Issue Panels • 8:45 - 9:45

| Code | Topic | Presenter |
|--|---|--|
| PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUES | | |
| IP17 | DERIVING UTILITY MEASURES FROM DISEASE-SPECIFIC QUALITY OF LIFE INSTRUMENTS: DOES MAPPING TO GENERIC UTILITY INSTRUMENTS ADEQUATELY CAPTURE THE PATIENT PERSPECTIVE IN ECONOMIC EVALUATION? | MODERATOR: SAMUEL ABALLÉA PANELISTS: LINDA ABETZ-WEBB, KEITH TOLLEY, CLÉMENT FRANÇOIS |

Research Posters • SESSION 4 • 08:45 - 14:00

| Code | Topic | Presenter |
|--|--|--|
| RESEARCH ON METHODS : CLINICAL OUTCOMES METHODS | | |
| PRM14 A14 | METHODOLOGICAL ISSUES WITH KEY DRUG VALUE FRAMEWORKS | KLOC K, LACH S, CHOUAID C, BORGET I, RÉMUZAT C, TOUMI M |
| PRM15 A15 | CURRENT AND POTENTIAL FUTURE CHANGES IN THE METHODOLOGY OF EMERGING VALUE FRAMEWORKS | KLOC K, LACH S, CHOUAID C, BORGET I, RÉMUZAT C, TOUMI M |
| RESEARCH ON METHODS - COST METHODS | | |
| PRM49 B22 | REPORTED LIMITATIONS IN ECONOMIC MODELS FOR TREATMENTS OF SCHIZOPHRENIA: A SYSTEMATIC LITERATURE REVIEW | ZHOU J, MILLIER A, DOREY J, ABALLÉA S, TOUMI M |
| PRM52 B25 | SYSTEMATIC REVIEW OF COHORT-LEVEL ECONOMIC MODELS FOR ANTIPSYCHOTICS IN SCHIZOPHRENIA | ZHOU J, MILLIER A, DOREY J, ABALLÉA S, TOUMI M |
| RESEARCH ON METHODS - MODELING METHODS | | |
| PRM130 E21 | VACCINE EFFICACY, EFFECTIVENESS, OR IMPACT: WHICH ONE TO CHOOSE IN ECONOMIC EVALUATIONS OF VACCINES? | STANDAERT B, DORT T, TOUMI M |
| RESEARCH ON METHODS - STUDY DESIGN | | |
| PRM230 H31 | TRENDS IN PRAGMATIC CLINICAL TRIALS | KLOC K, PISARCZYK K, LACH S, RÉMUZAT C, TOUMI M |
| INFECTION - PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE STUDIES | | |
| PIN82 I7 | IMPACT OF CYTOMEGALOVIRUS INFECTION AND TREATMENT ON PATIENT-REPORTED OUTCOMES IN HAEMATOPOIETIC CELL TRANSPLANT RECIPIENTS | HAKIMI Z, ENGLISH M, HAKIMHAWKEN N, DOREY J, ABALLEA S, ODEYEMI I, TOUMI M |
| SENSORY SYSTEMS DISORDERS - COST STUDIES | | |
| PSS21 M33 | COST-EFFECTIVENESS OF A 0.2 µG/DAY FLUOCINOLONE ACETONIDE (FAC) IMPLANT IN THE TREATMENT CHRONIC DIABETIC MACULAR OEDEMA (DMO) IN THE UK | BEIDERBECK A, ABALLEA S, POCHOPIEN M, MAMAN K, ZUR R, TOUMI M |



Michał Pochopien
MSc
Senior Analyst, HEOR



Cécile Rémuzat
PharmD, MSc
Senior Manager,
Pricing & Market Access



Steve Sherman
Principal Consultant,
HEOR



Mondher Toumi
MD, PhD, MSc
CEO



creativ@creativ-ceutical.com
+33 (0)1 76 70 47 90
www.creativ-ceutical.com